Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerM Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Cancer Immunology Research|February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse EventsDylan J Martini, Lana Hamieh, Rana R McKay, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureNizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinomaRobert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancerM Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Cancer Immunology Research|February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse EventsDylan J Martini, Lana Hamieh, Rana R McKay, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
European Journal of Cancer (Oxford, England : 1990)|November 15, 2011
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failureNizar M Tannir, Yu-Ning Wong, Christian K Kollmannsberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2023
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Lancet (London, England)|November 8, 2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialBrian I Rini, Bernard Escudier, Piotr Tomczak, et al.
Pageof 13